Compound guide
A pathway-focused guide to molecular mechanisms, published evidence, and the limits of interpretation.
Overview
APX-3 is Apex’s catalog name for a single-peptide research compound that engages GLP-1, GIP, and glucagon signaling—an approach sometimes informally described as “GLP-3.”
All three targets are class B G-protein-coupled receptors. APX-3 binding activates Gs-protein signaling, raises intracellular cyclic AMP, and produces different downstream effects depending on the receptor and tissue involved.
Randomized phase 2 studies and a peer-reviewed phase 3 diabetes trial have reported body-weight and metabolic outcomes. APX-3 remains investigational and is not FDA approved. Published results apply only to the specific investigational formulations, participants, study designs, and endpoints evaluated.
Research model
These receptors, enzymes, and signaling networks define the primary laboratory questions associated with this research material.
In pancreatic beta cells, GLP-1 receptor signaling raises cyclic AMP and activates PKA and EPAC pathways that amplify glucose-dependent insulin release. In the brain and digestive system, the pathway promotes satiety and slows gastric emptying.
GIP receptors are found in pancreatic beta cells and other metabolic tissues. Their Gs–cyclic-AMP signaling also amplifies insulin release when glucose is elevated. Cell studies indicate that APX-3 has especially strong activity at this receptor.
Glucagon receptors are concentrated in the liver. Their cyclic-AMP and PKA signaling can increase hepatic glucose output, but it can also increase fatty-acid oxidation, reduce lipid synthesis, and raise energy expenditure. The paired incretin activity is intended to counterbalance the glucose-raising side of glucagon signaling.
Map the research pathway
Follow each target through its intracellular signal, the model being observed, and the evidence boundary that governs interpretation.
Activates PKA and EPAC signaling inside the cell.
In pancreatic beta cells, GLP-1 receptor signaling raises cyclic AMP and activates PKA and EPAC pathways that amplify glucose-dependent insulin release. In the brain and digestive system, the pathway promotes satiety and slows gastric emptying.
Pathway activity does not establish safety, efficacy, or suitability for personal use.
Strengthens nutrient-responsive signaling inside the cell.
GIP receptors are found in pancreatic beta cells and other metabolic tissues. Their Gs–cyclic-AMP signaling also amplifies insulin release when glucose is elevated. Cell studies indicate that APX-3 has especially strong activity at this receptor.
Pathway activity does not establish safety, efficacy, or suitability for personal use.
Sends a fuel-mobilization signal through the cell.
Glucagon receptors are concentrated in the liver. Their cyclic-AMP and PKA signaling can increase hepatic glucose output, but it can also increase fatty-acid oxidation, reduce lipid synthesis, and raise energy expenditure. The paired incretin activity is intended to counterbalance the glucose-raising side of glucagon signaling.
Pathway activity does not establish safety, efficacy, or suitability for personal use.
Pathways examined together
Research interpretation
In pancreatic beta cells, GLP-1 receptor signaling raises cyclic AMP and activates PKA and EPAC pathways that amplify glucose-dependent insulin release.
GIP receptors are found in pancreatic beta cells and other metabolic tissues.
Glucagon receptors are concentrated in the liver.
Randomized phase 2 studies and a peer-reviewed phase 3 diabetes trial have reported body-weight and metabolic outcomes. APX-3 remains investigational and is not FDA approved. Published results apply only to the specific investigational formulations, participants, study designs, and endpoints evaluated.
Read the evidence
Continue exploring
More compounds organized within the metabolic signaling research area.
AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone and was developed to study lipid metabolism separately from full-length growth-hormone signaling.
Open compound guide ↗
5-Amino-1MQ is a small-molecule inhibitor used to study nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide and methyl-donor metabolism.
Open compound guide ↗
APX-2 is the catalog name for tirzepatide (LY3298176), a peptide that engages two incretin receptors: GIPR and GLP-1R.
Open compound guide ↗One important note
APX-3 has randomized human data for obesity, type 2 diabetes, and liver-fat outcomes. The reported effects and adverse events belong to the specific formulations, doses, populations, and study conditions cited below.
This guide summarizes molecular mechanisms, published evidence, and evidence limits in everyday language. It is educational information, not medical advice or instructions for personal use. Products offered on this site are intended exclusively for laboratory research and are not for human or veterinary use.
